CTI investigated by SEC
This article was originally published in The Gray Sheet
Executive Summary
The Securities & Exchange Commission and U.S. Attorney request documents from Computerized Thermal Imaging's management related to possible insider trading malfeasance, company states in recent 10-K filing. While CTI maintains the allegations are without merit, it believes the charges will greatly impair its ability to raise funds. FDA's Radiological Devices Advisory panel voted against approval of the company's BCS 2100 breast imaging system; CTI continues to work with the agency to remedy deficiencies in its application (1"The Gray Sheet" May 25, 2003, In Brief)...
You may also be interested in...
CTI working to overturn FDA decision
Computerized Thermal Imaging reports May 22 it has "provided additional analysis and...had productive discussions with the FDA staff" on the agency's "non-approvable" letter for BCS 2100 thermal breast imaging system. Rejection of the PMA followed a December panel meeting in which members faulted the Portland, Ore. firm's 173-patient "post-hoc" retrospective study as inadequately powered (1"The Gray Sheet" Dec. 16, 2002, p. 11)...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.